“Managing hundreds of products across multiple species requires a different approach to network strategy than human pharma,” explains Bernhard Boehm, Head of External Manufacturing for Animal Health at Boehringer Ingelheim.

Bernhard Boehm leads external manufacturing for animal health as VP of 3PM at Boehringer Ingelheim, bringing nearly 20 years of pharmaceutical experience across regulatory, quality, R&D, and site management roles before transitioning to animal health five years ago.

Ahead of CDMO Live, Bernhard explains how animal health manufacturing differs fundamentally from human pharmaceuticals, requiring specific strategies to manage a complex portfolio across multiple species while facing tighter margins and diverse customer needs.

Read Boehringer Ingelheim’s Six Strategic Approaches to External Manufacturing Networks